Back to top

cell-therapy: Archive

Zacks Equity Research

CRISPR (CRSP) Q4 Earnings Top on Collaboration Revenues, Stock Up

CRISPR (CRSP) gains on encouraging fourth-quarter 2023 results, beating both earnings and revenue estimates on the back of collaboration revenues received from Vertex.

VRTXPositive Net Change PBYINegative Net Change ADMAPositive Net Change CRSPNegative Net Change

Zacks Equity Research

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

RHHBYNegative Net Change SRPTPositive Net Change ADMAPositive Net Change IMCRPositive Net Change

Zacks Equity Research

Vor Bio (VOR) Up on Positive Update From AML Cell Therapy Study

Vor Bio (VOR) stock gains after dosing the first patient in its phase I/II study of novel cell therapy, VCAR33 (Allogenic), to treat AML. The company extends its cash runway into the second half of 2025.

PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change VORPositive Net Change

Zacks Equity Research

Sana Bio (SANA) Stock Rallies 105% in 3 Months: Here's Why

Sana Bio (SANA) rallies 105% after the company reports encouraging pipeline progress with its candidates, SC291 and SC262, for oncology and autoimmune indications.

PBYINegative Net Change ADMAPositive Net Change ACADNegative Net Change SANANegative Net Change